Jonasch E - Search Results

1

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.

Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. Liu XD, et al. Among authors: jonasch e. Nat Commun. 2020 May 1;11(1):2135. doi: 10.1038/s41467-020-15959-6. Nat Commun. 2020. PMID: 32358509 Free PMC article.

2

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Ueno NT, et al. Among authors: jonasch e. Blood. 2003 Nov 15;102(10):3829-36. doi: 10.1182/blood-2003-04-1022. Epub 2003 Jul 24. Blood. 2003. PMID: 12881308 Free article. Clinical Trial.

3

Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes.

Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Ahrar K, et al. Among authors: jonasch e. J Vasc Interv Radiol. 2005 May;16(5):679-88. doi: 10.1097/01.RVI.0000153589.10908.5F. J Vasc Interv Radiol. 2005. PMID: 15872323

4

Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.

Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Rodney A, et al. Among authors: jonasch e. Cancer. 2006 May 15;106(10):2143-7. doi: 10.1002/cncr.21894. Cancer. 2006. PMID: 16598751 Free article. Clinical Trial.

5

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Tannir N, et al. Among authors: jonasch e. Cancer. 2006 Aug 1;107(3):497-505. doi: 10.1002/cncr.22038. Cancer. 2006. PMID: 16795067 Free article. Clinical Trial.

6

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.

Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Tannir NM, et al. Among authors: jonasch e. Cancer. 2006 Nov 1;107(9):2254-61. doi: 10.1002/cncr.22253. Cancer. 2006. PMID: 17029276 Free article. Clinical Trial.

7

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG. Kassouf W, et al. Among authors: jonasch e. J Urol. 2007 Nov;178(5):1896-900. doi: 10.1016/j.juro.2007.07.037. Epub 2007 Sep 17. J Urol. 2007. PMID: 17868729

8

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.

Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Jonasch E, et al. Br J Cancer. 2008 Apr 22;98(8):1336-41. doi: 10.1038/sj.bjc.6604266. Epub 2008 Mar 25. Br J Cancer. 2008. PMID: 18362942 Free PMC article.

9

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Margulis V, et al. Among authors: jonasch e. J Urol. 2008 Jul;180(1):94-8. doi: 10.1016/j.juro.2008.03.047. Epub 2008 May 15. J Urol. 2008. PMID: 18485389

10

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. Tannir NM, et al. Among authors: jonasch e. J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635226 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

359 results

Search Page

Filters